| 1 |
Development of PROTAC-based **** degrader for promoting cartilage regeneration in osteoarthritis |
| Small Molecules |
Osteoarhtritis |
Tankyrase |
Hit |
Seoul National University |
RS-2023-00217266 |
|
| 2 |
Development of T cell-recruiting bispecific antibodies targeting blood antigen-specific B cells for ABO-incompatible solid organ transplantation |
| Antibody |
Organ Failure (incompatible blood type) |
ABO BCR, CD3 |
Hit |
Korea Advanced Institute of Science and Technology |
HN21C1024 |
|
| 3 |
|
| Others |
Bronchopulmonary Dysplasia(BPD) |
Ago2 |
Lead |
Samsung Medical Center |
HN22C0414 |
|
| 4 |
Development of multi-functioning lead compounds for lymphedema |
| Small Molecules |
Lymphedema |
Nrf2 |
Lead |
RAPPELER |
HN22C0095 |
|
| 5 |
A Study on the lead optimization for the development of new antibody drugs for androgenic alopecia and alopecia areata |
| Antibody |
Hair Loss |
CXCL12 |
Lead |
Epibiotech |
HN22C0027 |
|
| 6 |
Mitochondrial transplantation as a novel treatment for sensorineural hearing loss |
| Others |
Hearing loss |
Sensorineural hearing loss (with mitochondrial defects) |
Candidate |
Paean Biotechnology Inc. |
RS-2023-00283926 |
|
| 7 |
Candidate optimization of ARBM-101 as an innovative Wilson's disease drug |
| Peptide |
Wilson disease |
Cu2+ |
Candidate |
ARBORMED |
RS-2023-00218925 |
|
| 8 |
Development of a Tie2-activating antibody for treating acute kidney injury (AKI) |
| Antibody |
Acute Kidney Injury |
Tie2 |
Candidate |
MabTics Co., Ltd. |
RS-2023-00217918 |
|
| 9 |
Development of a highly stable and safe macrocyclic gadolinium-based contrast agent for hepatobiliary MRI imaging |
| Others |
MRI contrast agent |
Gd-ligand |
Candidate |
PharmGen Science, Inc. |
HN22C0196 |
|
